biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA
MAIA Biotechnology
Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non
Company details
- Status
- Public
- HQ
- honolulu, USA
- Founded
- 2013
- Employees
- 5
- Programs
- 8
- Drugs
- 19
- Patents
- 10
ateganosine
Phase 1 · small molecule · Resectable Hepatocellular Carcinoma
ateganosine for Resectable Hepatocellular Carcinoma is a Phase 1 program (small_molecule) at MAIA Biotechnology with 1 ClinicalTrials.gov record(s).
Internal code SCCC-12225; STU20251351
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MAIA Biotechnology
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Resectable Hepatocellular Carcinoma
- Status
- active
- Trials
- 1